The nation of Zimbabwe has rejected a substantial American healthcare agreement worth 367 million US dollars (£272m) spanning five years over Washington's demand for confidential data.
This rejection came to light following a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa deemed the deal was "unbalanced".
An official representative has since clarified that the United States was seeking biological samples for research and commercial gain while was not willing to share the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged further dialogue to find a agreement acceptable to all parties so the country's vital HIV treatment initiative can continue.
Wider Implications
This rejection comes after a similar case in Kenya, where a court suspended a related deal with the US after concerns were raised about the safety of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump argued its expenditure was "inefficient" and his administration was seeking direct bilateral deals to boost transparency and responsibility.
Based on statements, Sixteen African countries have to date signed these new agreements, representing over $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy via US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to share its genetic material and health information for a long time, without any corresponding assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"In essence, our country would supply the basic resources for medical research without any assurance that the end products would be available to our people if a new health crisis emerge."
National Interest and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were undermining structures already set up via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This mechanism is intended to ensure that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage further dialogue with our US partners on how future collaboration might be structured in a way that honours the independence and dignity of both nations."
Health Experts Reaction
A leading public health body expressed it acknowledged the official position, but urged that talks need to persist given that much of the nation's Aids initiatives were funded by foreign aid.
"In cases where specific concerns arise, such as those relating to data governance or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," the group commented.
The situation underscores the complex tensions between receiving vital foreign assistance and safeguarding a country's data in an ever more interconnected world.